Imaging, Cognition, and Parkinson's Disease—An Overview

No abstract is available for this paper.

• Publication year

  2010

• Venue

  US neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.17925/USN.2010.05.02.26
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The clinical impression of severity index for Parkinson's disease: International validation study

  2009cited by this paper
• Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

  2008cited by this paper
• Imaging amyloid deposition in Lewy body diseases

  2008cited by this paper
• [11C]PIB binding in Parkinson's disease dementia

  2008cited by this paper
• Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.

  2008cited by this paper
• Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging

  2008cited by this paper
• Metabolic correlates of subthalamic nucleus activity in Parkinson's disease.

  2008cited by this paper
• Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

  2008cited by this paper
• Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study.

  2008cited by this paper
• Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning

  2008cited by this paper
• In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies

  2007cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• Assessment of the progression of Parkinson's disease: a metabolic network approach.

  2007cited by this paper
• Metabolic brain networks associated with cognitive function in Parkinson's disease

  2007cited by this paper
• Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

  2007cited by this paper
• Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia

  2006cited by this paper
• Network modulation in the treatment of Parkinson's disease.

  2006cited by this paper
• Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia

  2006cited by this paper
• Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease

  2006cited by this paper
• Differences in neuropathologic characteristics across the Lewy body dementia spectrum

  2006cited by this paper
• Functional imaging of sequence learning in Parkinson's disease.

  2006cited by this paper
• Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease

  2005cited by this paper
• Neuroimaging and therapeutics in movement disorders

  2005cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

  2005cited by this paper
• Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.

  2005cited by this paper
• Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism

  2004cited by this paper
• Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease

  2004cited by this paper
• Executive processes in Parkinson's disease: FDG‐PET and network analysis

  2004cited by this paper
• Cognitive dysfunction and dementia in Parkinson’s disease

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

  2004cited by this paper
• Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies

  2004cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Activation of basal ganglia loops in idiopathic Parkinson’s disease: a PET study

  2003cited by this paper
• Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.

  2002cited by this paper
• Cognitive impairments in advanced PD without dementia

  2002cited by this paper
• Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease.

  2002cited by this paper
• Searching for a baseline: Functional imaging and the resting human brain

  2001cited by this paper
• Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.

  2000cited by this paper
• Mental symptoms in Parkinson's disease are important contributors to caregiver distress

  1999cited by this paper

• No citing papers are available for this paper.